ICER has completed a draft report on the comparative clinical effectiveness and comparative value of all major management options for low-risk prostate cancer. The report summarizes findings from three previous ICER appraisals, and also includes the results of new decision-analytic modeling incorporating all treatment approaches as well as a clinician decision guide. .
The report is published as a draft; public comments are encouraged. The comment period, originally scheduled to end October 16, 2009, has been extended to November 13, 2009. Comments may be submitted online at the report page or via e-mail to email@example.com.